Gentamicin-Curtis et al.
M Bm u 539 filtration during haemodialysis. However, similar peak plasma levels were obtained when gentamicin was given intravenously immediately before dialysis, suggesting that the size of the distribution volume of gentamicin is not affected by haemnodialysis. Further, one patient (Case 2) did not require ultrafiltration during haemodialysis. One of the major problems of intermittent haemodialysis is infection of the Scribner cannulation site. Those infections due to Gram-negative organisms are notoriously difficult to treat, and often result in loss of the cannula site (Pendras, 1964; Pendras and Erickson, 1966; Johnson et al., 1966) . Previous to the present study, two shunt-site infections due to Ps. pyocyanea resulted in the loss of the shunt site within 48 hours, in spite of treatment with colistin sulphate (Colmycin) . In the two patients reported here (Cases 1 and 3) there was clinical evidence of infection of the cannula site characterized by local inflammation, pain, tenderness, and the production of pus from which Ps. pyocyanea was isolated. On treatment with gentamicin there was loss of pain and tenderness, and in Case 1 the cannula continued to function normally until the 24th day, when a mycotic aneurysm ruptured, necessitating removal of the shunt. In Case 3 the cannula continued to function normally until the 26th day, when clotting of the shunt occurred. Declotting was not attempted because of the risk of septicaemia or septic pulmonary embolism; the cannula site was therefore changed.
In all previous studies with gentamicin the intramuscular route of* administration had been used. When Prolonged elevation of plasma gentamicin levels was observed in the patients.
The plasma disappearance rate of gentamicin was significantly increased during haemodialysis by means of a modified Kill dialyser with cuprophane membranes (PT 150). It has been shown that gentamicin is dialysable from plasma with this membrane.
In-patients undergoing twice-weekly haemodialysis on a modified Kiil dialyser with the PT 150 membrane a modified dosage schedule is required; it is suggested that 1 mg. of gentamicin per kg. body weight be given intravenously at the end of each dialysis.
The risk of severe infection of the ventricles and meninges by Gram-negative bacteria appears inseparable from extensive neurosurgical procedures. Infection with many strains of Pseudomonas can be successfully treated by the use of intrathecal and intramuscular polymnyxin B methane sulphonate (Newman and Stewart, 1964) , but a high proportion of the enterobacteriaceae found in these sites are not sensitive to antibiotics suitable for intrathecal therapy.
Reports from many workers Jao and Jackson, 1964; . Clinical trials of the antibiotic demonstrate its value in the treatment of urinary infections caused by, Gramnegative bacteria (Jao and Jackson, 1964) , especially those caused by pseudomonads, and in the treatment of pseudomonas burn sepsis (Stone et al., 1965 
Drug Assay
The use of Bacillus subtilis (Jao and Jackson, 1964) , staphylococcus 209P, or Sarcina lutea .
Preliminary Laboratory Investigations
Routine clinical isolates of Gram-negative bacteria from all sources were tested against gentamicin-sensitivity discs (Table I) . Zones of inhibition with diameters over 15 mm. were regarded as fully sensitive, zones between 10 and 15 mm. showed restricted sensitivity, and organisms with zones below 10 mm. were regarded as resistant. A proportion of the isolates shown in Table I , including all cases where gentamicin was contemplated, were further tested in liquid medium (Table 11 ). The results indicated that many infections due to these organisms might be amenable to treatment with gentamicin provided effective levels could be attained in vivo.
Clinical Observations
Treatment of a number of patients with urinary infections due to these organisms was begun, and will be the subject of another publication.
Three patients with meningitis and ventriculitis were treated with gentamicin. Gentamicin-Newman and Holt #Fig. 1). Examination of the C.S.F. after 24 hours showed a low level of gentamicin (less than 1 zIg./ml.) and no detectable serum level. The C.S.F. culture was still positive.
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After two days the C.S.F. culture was still positive, and in'significant serum levels were found. Assay of gentamicin in the C.S.F.
showed a residual level of less than 1 pg./ml. 24 hours after a dose. The minimum inhibitory concentration for the organism was 1-2 pg./ml. and the minimum bactericidal concentration was the same.
As a result of experience with Case 1 the dosage was doubled by the intraventricular route and C.S.F. levels rose to about 1.5 ,ug./ml. (residual after 24 hours), but the serum levels remained very low (less than 0.5 pg./mi. at any time). On the fourth day of treatment the intramuscular dose was also doubled and serum levels rapidly rose to between 1 and 2 /xg./ml. During the next four days the organisms in the C.S.F. became less numerous and culture was sterile on the tenth day of treatment. Intraventricular therapy continued for another three days and intramuscular for a further week, during which time C.S.F. levels fell to zero and serum levels remained at between 1 and 2 pg./ml. There was no recurrence of the infection.
Protein and cells rose slightly on the second day of treatment and fell steadily thereafter. There was no evidence of toxicity of the drug. Intramuscular dosage continued at the same rate for another four days, during which the daily intraventricular dose was increased to 200 pg. and then to 400 pg. On the third day of treatment the C.S.F. from the ventricles was sterile and the culture never again became positive. On the sixth day the intraventricular dose was increased to 1 mg. with no ill effect, and, though raps at short intervals after a dose revealed higher C.S.F. levels, these fell rapidly during the succeeding 24 hours.
The intramuscular dose was then doubled (2 mg./kg./day), and for the next three days higher C.S.F. levels were obtained (from 2 to 7 ,ug./ml.). Intraventricular administration then ceased and the C.S.F. levels fell away to nil, but on continuing intramuscular dosage at the higher level serum assays gave results of 1 pg./ml. Colonization of the valve had occurred during the ventriculitis, and, as expected, had persisted throughout treatment. The valve was changed again under cover of intramuscular therapy alone and no recurrence of the infection occurred.
Levels of gentamicin in the urine throughout the course of treatment varied widely, but would probably have been inadequate for the treatment of a sensitive urinary infection until the intramuscular dose was doubled.
The blood urea varied during treatment between 33 and 39 mg./ 100 ml., and no significant change in the blood picture or urine were seen. The C.S.F. protein and cells fell slowly during treatment, and no pleocytosis or rise in protein was seen as a result of the intraventricular injections.
Case 2
A baby with a meningomyelocele closed on the day of birth developed ventriculitis due to Ki. aerogenes 10 days after operation.
Gentamicin was begun immediately at the standard dose of 1 mg./ kg./day with 0.5 mg. daily intraventricularly (Fig. 2) . A baby who had a meningomyelocele repaired the day after birth developed meningitis three weeks later due to Ki. aerogenes. The organism was sensitive only to cephaloridine and gentamicin, and treatment was begun with gentamicin at the double standard dose intramuscularly-that is, 2 mg./kg./day-and 1 mg. intraventricularly daily (Fig. 3) . The C.S.F. was sterilized within 24 hours, and C.S.F. levels of gentamicin rose rapidly within that time to 3 ug./ml. The serum level also rose rapidly to 1 pig./ml. Intraventricular treatment continued for five days and intramuscular for seven days, with a further week of intramuscular dosage reduced to the standard rate of 1 mg./ kg./day.
The infection did not recur and a Spitz-Holter valve was successfully inserted during the period of intramuscular treatment. No toxic or side effects were seen clinically or in the blood picture or urine.
Comment
In each case the sensitivity of the organism to the drug was checked at frequent intervals and the minimum inhibitory concentrations did not change. In Case 2 the minimum bactericidal concentration doubled during treatment but was still only '5-10 jg./ml. on the last isolation. In Case 3 a strain of Ps. pyocyanea colonizing the back wound was found to be resistant to 50 jAg. of gentamicin per ml., an unusually high level for this organism; and in Case 2 a strain of K1. aerog:nes apparently identical with that in the C.S.F., and with the same minimum inhibitory concentration and 27 May 1967 Gentarnicin-Newman and Holt BMRISII minimum bactericidal concentration, was found in the patient's stools after treatment.
Discussion From a comparison of the three cases it appears that in order to achieve and maintain an effective level of the drug in the C.S.F. it must not only be given intrathecally but a minimal level must also be maintained in the blood. In Case 1 this state of affairs was accomplished only after doubling the intramuscular dosage, and the necessity for this was borne out in Case 2 when the C.S.F. was sterilized only after doubling the dosage. In Case 3 rapid sterilization of the C.S.F. occurred, probably as a result of starting treatment on the increased dosage schedule.
It will be seen from Figs. 1-3 that without intraventricular administration it is most unlikely that an effective level could be reached in the C.S.F. by intramuscular dosage alone. This is in accordance with our experience in the treatment of similar conditions with other drugs. In the case reported by , treated with intramuscular gentamicin alone the C.S.F. levels were very low and would be effective only against the most sensitive organisms. It should be borne in mind that the C.S.F. volume in these babies, all with some degree of hydrocephalus, was greater than normal, and smaller intraNentricular doses would probably be appropriate in children with ventricles of normal size.
It has been reported by other workers that various side-effects of gentamicin have occurred, particularly when the blood level has exceeded about 10 ttg./ml. It appears from our work on these three cases, and on children receiving the drug for other infections, that this level is unlikely to be reached, at least in young children, on normal or double intramuscular dosage. Indeed, it seems likely that in the treatment of tissue infections dependent on an effective blood level of the drug at least double the recommended intramuscular dose is necessary. It is possible that young children excrete the drug more rapidly than adults, but experience with other cases suggests that the danger of accumulation of the drug in the blood cannot be ignored, and that its use in children should be controlled at present by frequent serum assays.
In all three cases careful watch was kept for evidence of toxicity of the drug. No such effects were seen. The blood picture remained unchanged apart from the incidence of a leucocytosis in each case, and the urine showed no abnormalities. The blood urea was checked frequently in all cases and showed only minor fluctuations. All of these patients were small babies with congenital abnormalities of the nervous system, but no effects on the central nervous system were seen which might have been attributed to the use of gentamicin.
It has been our experience that colonization of valves used for the relief of hydrocephalus can never be eradicated by the use of antibiotics in the C.S.F. In Case 1, where this state of affairs existed, gentamicin also failed to sterilize the valve, though the ventricular C.S.F. was quickly sterilized.
Conclusions
In these three cases of ventriculitis due to organisms not easily dealt with by other drugs, gentamicin eradicated the infection successfully. It appears that in treating such infections it is essential to give the drug intraventricularly and to give simultaneously double the recommended intramuscular dose. No toxic effects were seen in these three cases, but as very little information exists on the use of gentamicin in children treatment should be controlled at present by frequent serum assays. The successful eradication of these three infections suggests that the use of gentamicin should be considered in infections of this kind where the choice of drugs is limited and results are often disappointing.
Summary
Three babies with meningitis and ventriculitis were successfully treated with gentamicin. Preliminary laboratory investigations showed gentamicin to be active against a wide range of organisms, particularly those commonly encountered in this condition. Frequent assays of cerebrospinal fluid and serum during treatent showed intraventricular administration to be essential together with a larger intramuscular dose than that recommended. Laboratory data and methods are presented in detail. No toxic effects attributable to the drug were seen, and it is suggested that the use of gentamicin should be considered in cases of this kind.
ADDENDUM.-Since this paper was written another similar case has been successfully treated with gentamicin. A baby with well-established Ki. aerogenes meningitis and thick purulent C.S.F. was treated in the same way as Case 3. The C.S.F. was sterilized in 15 days and intramuscular therapy continued for a further month. In all, 270 mg. was given intramuscularly without side-effects.
We are grateful to our colleagues at Queen Mary's Hospital for Children for their help and co-operation in treating these patients, and particularly to Mr. H. B. Eckstein and Mr. D. M. Forrest, under whose care they were admitted. We are also indebted to the nursing staff for collection of numerous specimens.
The gentamicin used in this work was supplied by British Schering Limited.
